Cargando…
Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data
BACKGROUND: Targeting programmed death protein 1 (PD-1) or its ligand PD-L1 is a promising therapeutic approach for many types of cancer in which PD-L1 is overexpressed. However, data on PD-L1 expression levels in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are limited and contradicto...
Autores principales: | Rösner, Erik, Kaemmerer, Daniel, Sänger, Jörg, Lupp, Amelie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468575/ https://www.ncbi.nlm.nih.gov/pubmed/36067541 http://dx.doi.org/10.1016/j.tranon.2022.101526 |
Ejemplares similares
-
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours
por: Rösner, Erik, et al.
Publicado: (2021) -
Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61
por: Ehms, Blanca, et al.
Publicado: (2022) -
Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin
por: Mai, Rebekka, et al.
Publicado: (2019) -
Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy
por: Kaemmerer, Daniel, et al.
Publicado: (2015) -
Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study
por: Beyer, Anna-Sophia Liselott, et al.
Publicado: (2022)